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Modified use of the Hemodialysis Reliable
Outflow (HeRO) graft for salvage of threatened
dialysis access
Bassan J. Allan, MD, Angela T. Prescott, MD, Marwan Tabbara, MD, Arash Bornak, MD, and
Lee J. Goldstein, MD, Miami, Fla
The Hemodialysis Reliable Outflow (HeRO) graft (Hemosphere Inc, Eden Prairie, Minn) offers a new option to provide
upper extremity arteriovenous (AV) dialysis access in patients with central venous occlusive disease. Creative use of this
device can allow for salvage of failing or threatened AV fistulas and grafts. We present two patients who underwent a
modified implantation of the HeRO device for immediate salvage of a malfunctioning AV access. Ipsilateral central
venous occlusions were successfully overcome by anastomosing a HeRO device to the existing AV access and tunneled
across the chest to the contralateral internal jugular vein. (J Vasc Surg 2012;56:1127-9.)
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aLong-term hemodialysis access is an increasing prob-
lem, with a growing number of patients becoming
hemodialysis-dependent and spending longer lengths of
time on hemodialysis. Despite its relatively new use, recent
data suggest similar function and patency rates of Hemodial-
ysis ReliableOutflow (HeRO) grafts (Hemosphere Inc, Eden
Prairie, Minn) compared with arteriovenous (AV) grafts,1,2
alongwith decreased bacteremia, improved patency rates, and
improved adequacy of dialysis compared with tunneled dialy-
sis catheters in patients with difficult access.1
Failed AV fistulas or grafts are often the result of
access-related thromboses, infections, and multiple central
venous occlusions. In many instances, such patients will be
faced with a malfunctioning upper extremity AV access due
to worsening central venous outflow stenosis. We present a
modified technique in which theHeRO device was used for
the salvage of a functioning, yet threatened, upper extrem-
ity AV access in the setting of extremely limited central
venous outflow options.
CASE REPORTS
Patient 1. A 69-year-old diabetic African American man,
with end-stage renal disease and who had received hemodialysis for
5 years, presented complaining of right arm swelling and pain,
worsened by hemodialysis. His dialysis access consisted of a right 4-
to 7-mm tapered brachioaxillary AV graft (AVG) of expanded
polytetrafluoroethylene. He had previously undergone a left basilic
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ubsequently became infected and was excised.
In a dedicated special-procedures hybrid operating room, a
stulogram demonstrated an occlusion of the right subclavian vein
ithout clear reconstitution of the right internal jugular vein (IJV)
r subclavian confluence, along with extensive collateralization.
ndovascular attempts at recanalization of the right subclavian
ein were unsuccessful. Central venography from a femoral vein
pproach demonstrated an occluded right IJV, but a patent supe-
ior vena cava, left innominate vein, left subclavian, and IJV.
Ultrasound guidance was used to access the left IJV, and a wire
as passed into the right atrium under fluoroscopic guidance.
fter central venous access to the superior vena cava was estab-
ished, the venous outflow component of the HeRO device was
ntroduced after serial dilation of the tract. The device was tun-
eled subcutaneously across the anterior chest wall to a counter
ncision at the right (contralateral) deltopectoral groove, where the
-mmHeRO graft was coupled to the venous outflow component
Fig, arrow). Care was taken to maintain the tunnel of the HeRO
evice under the sternal notch, and due to the rigidity of the
evice, no kinking was appreciated on fluoroscopy.
A 2.5-cm incision was made at the distal (venous) end of the
VG, and the HeRO graft was further tunneled from the coupler
ncision site to the AVG incision site in the upper arm. After obtaining
roximal and distal control and infusing intravenous heparin (3000
nits), the new polytetrafluoroethylene-HeRO system was anasto-
osed in an end-to-side fashion to the existing graft. A completion
stulogram performed through a micropuncture of the graft revealed
risk flow through the HeRO into the right atrium (Fig). The
perative time was approximately 4 hours. The patient had an esti-
ated blood loss of 200 mL and no intraoperative complications.
Dialysis was reinstituted the next day using the pre-existing
raft, with dialysis flow rates of 420 mL/min compared with
reoperative dialysis flow rates of 400 mL/min. The patient has
uccessfully continued hemodialysis through the HeRO device for
4 months, without complications and with relief of his preoper-
tive symptoms.
Patient 2. A 64-year-old man with a history of end-stage
enal disease and multiple failed bilateral upper extremity fistulas
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October 20121128 Allan et alhad been receiving chronic hemodialysis for 10 years. He was
evaluated after the dialysis unit noted clots in the equipment
tubing and loss of a palpable thrill over his right brachiocephalic
AV fistula, which had been created 2 years prior. After an initial
evaluation, the interventional radiology service successfully throm-
bectomized the fistula and performed a fistulogram that revealed
occlusion of the right subclavian/innominate veins, with unsuc-
cessful attempts at recanalization. A left IJV tunneled catheter was
placed to provide a viable dialysis access.
Given this patient’s ipsilateral central occlusions and no usable
arm veins, we opted to place a HeRO device as described in patient
1. The left tunneled dialysis catheter was exchanged for the venous
outflow component of the HeRO device, as previously described,3
positioned under fluoroscopic guidance, and anastomosed, as de-
scribed in patient 1, with the exception that no systemic anticoag-
ulation was given. A completion fistulogram revealed good flow
through the fistula, into the HeRO device, and into the right
atrium. The case was performed in a dedicated special-procedures
hybrid operating room suite and lasted 3 hours, with an estimated
blood loss of 100 mL.
Postoperatively, the patient had minor erythema around the
right chest incision, which was treated with a 10-day course of
Augmentin (GlaxoSmithKline, London, UK). He has continued
receiving dialysis through his native fistula with the modified
HeRO device outflow for 5 months, with no other complications.
The postoperative flow rate of dialysis was 450 mL/min compared
with a preoperative flow rate of 400 mL/min.
DISCUSSION
The rising number of chronic hemodialysis patients has
resulted in an increased incidence of failed AV accesses,
upper extremity venous hypertension, and limited central
venous outflow options.4,5 Surgical creativity in the setting
of salvaging threatened but functioning accesses with few
alternate placement sites becomes paramount. Previous
publications have documented successful implantation of
the HeRO as well as endovascular techniques to manage
occlusive episodes.3,6-8 We have presented another option
Fig. Completion fistulogram demonstrates flow into the
Outflow (HeRO) device. The arrow depicts the HeRO-e
component-coupling site. AVG, Arteriovenous graft; AXfor immediate salvage when the only central venous out-ow may be the contralateral IJV, allowing for continued
se of the functioning access and preservation of the graft
r fistula.
Endovascular therapy has become the standard of care for
psilateral central venous stenoses or occlusions that can be
raversed. National Kidney Foundation Disease Outcomes
uality Initiative guidelines recommend angioplasty com-
ined with stenting for elastic central vein stenoses or recur-
ent stenoses within a 3-month period.9 Primary patency rates
or these interventions are 12% to 29% at 12 months, with
umulative patency rates of 69% to 100%.10,11 Unfortunately,
hese procedures have limited patency and high recurrence
ates requiring multiple interventions and potential complica-
ions. Furthermore, a subset of patients has occlusions that
annot successfully be treated endovascularly and previous
ailed fistulas/grafts have exhausted all potentially usable ac-
ess sites. Throughout the past decade, numerous complex
urgical techniques have been offered to approach chronic
otal occlusions of the central veins. These have included
ypasses performed via sternotomy, claviculectomy, and long
ypasses from the upper extremity to the femoral venous
ystem. These approaches are highly invasive and carry signif-
cant morbidity and mortality.5
ONCLUSIONS
The patients described present a hybrid endovascular
nd minimally invasive open surgical approach whereby a
hreatened AV access with an ipsilateral central vein occlu-
ion was bypassed to the right atrium through the con-
ralateral jugular vein. Advantages of this approach include
alvage of the failing access, immediate use of access after
he procedure, and decreased need for temporary indwell-
ng catheters. This modified HeRO technique can serve as
n option for properly selected chronic hemodialysis pa-
ients with complex central venous stenoses.
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